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Abstract
Dietary mycoprotein decreases energy intake in lean individuals. The effects in overweight individuals are unclear, and the mechanisms remain to
be elucidated. This study aimed to investigate the effect of mycoprotein on energy intake, appetite regulation, and the metabolic phenotype in
overweight and obese volunteers. In two randomised-controlled trials, ﬁfty-ﬁve volunteers (age: 31 (95% CI 27, 35) years), BMI: 28·0 (95% CI 27·3,
28·7) kg/m2) consumed a test meal containing low (44g), medium (88g) or high (132g) mycoprotein or isoenergetic chicken meals. Visual analogue
scales and blood samples were collected to measure appetite, glucose, insulin, peptide tyrosine-tyrosine (PYY) and glucagon-like peptide-1 (GLP-1).
Ad libitum energy intake was assessed after 3 h in part A (n 36). Gastric emptying by the paracetamol method, resting energy expenditure and
substrate oxidation were recorded in part B (n 14). Metabonomics was used to compare plasma and urine samples in response to the test meals.
Mycoprotein reduced energy intake by 10% (280kJ (67kcal)) compared with chicken at the high content (P=0·009). All mycoprotein meals
reduced insulin concentrations compared with chicken (incremental AUClow (IAUClow): −8%, IAUCmedium: −12%, IAUChigh: −21%, P=0·004). There
was no signiﬁcant difference in glucose, PYY, GLP-1, gastric emptying rate and energy expenditure. Following chicken intake, paracetamol-
glucuronide was positively associated with fullness. After mycoprotein, creatinine and the deamination product of isoleucine, α-keto-β-methyl-N-
valerate, were inversely related to fullness, whereas the ketone body, β-hydroxybutyrate, was positively associated. In conclusion, mycoprotein
reduces energy intake and insulin release in overweight volunteers. The mechanism does not involve changes in PYY and GLP-1. The
metabonomics analysis may bring new understanding to the appetite regulatory properties of food.
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In the present context of the increasing worldwide prevalence
of obesity and type 2 diabetes mellitus (T2DM), there is a need
to understand the impact of food products on appetite regu-
lation and glycaemic control in overweight and obese people.
Of the three macronutrients, protein is recognised as the most
potent appetite suppressor both in rodents and in humans(1–3).
Research in the past two decades has shown that protein-rich
loads increase satiety and lead to decreased energy intake
acutely(2,4–7). Studies have demonstrated that protein supple-
mentation increases weight loss and limits both fat-free mass
loss and the decrease in energy expenditure, which normally
occurs during weight loss by energy restriction(8–11).
Increasing dietary ﬁbre intake has also been associated with
reduced energy intake(12–15). In particular, soluble viscous
ﬁbres are thought to delay gastric emptying, slow nutrient
absorption, and increase the production of anorectic gastro-
intestinal (GI) hormones, glucagon-like peptide-1 (GLP-1) and
peptide tyrosine-tyrosine (PYY), through bacterial fermentation
and production of SCFA(16–19).
Quorn™ products are vegetarian meat replacements com-
monly consumed in the UK. The main ingredient of Quorn™ is
mycoprotein, which is the RNA-reduced biomass produced
from the continuous fermentation of the ﬁlamentous fungus
Fusarium venenatum. Mycoprotein, as used typically, contains
Abbreviations: GAA, guanidinoacetic acid; GI, gastrointestinal; GLP-1, glucagon-like peptide-1; IAUC, incremental AUC; PYY, peptide tyrosine-tyrosine;
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25 g of solids, including 11 g of protein and 6 g of ﬁbre/100 g
(data from Marlow Foods Ltd). The ﬁbre content is attributed to
the cell wall and is composed of 2/3 branched 1–3 and 1–6
β-glucan and 1/3 chitin, creating a ﬁbrous chitin–glucan matrix
with low water solubility (88% insoluble). This ﬁbrous glucan–
chitin complex is speciﬁc to fungal mycelium and not frequently
present in human food.
Owing to its relatively high protein and ﬁbre content,
mycoprotein presents an attractive food product to improve
appetite regulation and postprandial glycaemic and insulin
responses in overweight and obese individuals at risk of
developing T2DM. Previous studies in lean individuals have
found that mycoprotein reduces postprandial glucose and
insulin concentrations(20), and energy intake at a subsequent
meal(21,22). There has only been one study in overweight
volunteers that did not show any reduction in energy intake
at 4 h(23). However, this study used half of the portion of
mycoprotein found in commercially available mycoprotein
products. Given previous observations, there is a need to
ascertain whether mycoprotein exerts a dose-dependent effect
on energy intake and glycaemic control in overweight and
obese individuals and to determine the mechanism through
which mycoprotein may exert its action. To the best of our
knowledge, there are no published studies investigating the
effect of mycoprotein on GI hormones.
The primary purpose of the present study was to investigate
the effect of low, medium, and high doses of mycoprotein on
energy intake and glucose homeostasis compared with iso-
energetic and protein-matched chicken meals in overweight
and obese individuals. We hypothesised that mycoprotein
would reduce acute energy intake in overweight and obese
volunteers compared with a macronutrient-matched chicken
meal in a dose-dependent manner by delaying gastric emptying
and increasing the release of PYY and GLP-1.
Methods
We undertook two randomised single-blinded controlled trials
to investigate the impact of mycoprotein (nutritional informa-
tion in Table 1) on appetite regulation. Part A investigated the
effect of three levels of mycoprotein compared with chicken on
appetite, acute and 24-h energy intake, glucose and insulin
concentrations, and PYY and GLP-1 concentrations. Part B
investigated the effect of the highest content of mycoprotein
used in part A compared with chicken on appetite, glucose and
insulin concentrations, gastric emptying, and energy expendi-
ture and substrate oxidation.
Subjects
Overweight and obese volunteers aged 18–65 years with a BMI
of 25–32 kg/m2 were recruited to take part in this randomised
controlled single-blinded study. This study was conducted
according to the guidelines laid down in the Declaration of
Helsinki, and all procedures involving human subjects were
approved by the Hammersmith and Queen Charlotte’s Research
Ethics Committee (Ref no. 09/H0707/51). Written informed
consent was obtained from all subjects. The trial was registered
on www.clinicaltrials.gov (NCT02053025). Travel expenses
to the research centre were reimbursed and participants
were compensated for their involvement based on their
participation rate.
Recruitment
Participants were recruited via posters placed around Imperial
College campuses in London, UK and internet advertising.
Potential participants were invited for a screening visit to check
eligibility at the National Institute for Health Research (NIHR)/
Wellcome Trust Clinical Research Facility at Imperial College
Healthcare NHS Trust, hereafter referred to as the research
centre. Anthropometric measurements, medical history and
haematological and biochemical blood screen were collected.
To be included, participants had to be overweight or obese with
a BMI of 25–32 kg/m2 but otherwise healthy (no medication or
chronic disease), aged 18–65 years, with no history of eating
behaviour disorder. Exclusion criteria included a history of
alcoholism or substance abuse within the past 12 months;
smoking; a medical or psychological condition that would
interfere with the ability to participate in the study; women who
were pregnant or breast-feeding or had a pregnancy within the
last year; and participation in another clinical trial or blood
donation within 3 months of study commencement. For part A,
participants were asked to taste three ad libitum commercially
available meals, which were similar in energy content and
composition, and asked to choose their favourite.
Sample size calculation
The sample size was calculated on the primary outcome, a
decrease in energy intake, using the study by Burley et al.(21).
Following an isoenergetic meal containing 27 g of protein from
mycoprotein or chicken, they reported a signiﬁcant 18%
difference in energy intake with an SD of 16. With a level of
statistical signiﬁcance set at α= 0·05 and a power of 90%, the
sample size n needed for this study was 27. To account for a
30% dropout, a minimum of thirty-ﬁve participants were
recruited to take part in the appetite study.
Table 1. Nutritional composition of mycoprotein
Per 100 g of mycoprotein
Energy (kJ) 356
Energy (kcal) 85
Protein (g) 11·0
Available carbohydrate (g) 2·0
Dietary fibre (g) 6·0
Fat (g) 3·0
MUFA (oleic acid) (g) 0·3
PUFA (g) 1·4
Linoleic acid (C18 : 2) (g) 1·0
α-Linolenic acid (C18 : 3) (g) 0·4
SFA (g) 0·4
Palmitic acid (C16 : 0) (g) 0·3
Stearic acid (C18 : 0) (g) 0·1
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Visit randomisation and preparation
All eligible participants attended a practice visit at the research
centre in order to acclimatise to the protocol and the research
environment. The order of the treatment visits was randomised
for each eligible participant following the screening visit using a
randomising web-based programme (www.random.org). In
addition to this acclimatising visit, part A included six visits and
part B included two visits. Participants did not need to complete
both parts to be included in the study. Visits were separated by
a washout period of 3–7 d. Participants were asked to refrain
from drinking alcohol and to avoid any strenuous exercise for
24 h before each visit. They were also asked to consume the
same evening meal and fast for 12 h before arriving for their visit
to limit variability at baseline.
Visit design
The sequence of events during each visit for both part A and B
is detailed in Fig. 1. Following a 12-h overnight fast, volunteers
were asked to arrive at the research centre at 08.30 hours. After
the insertion of the catheter, two fasting blood samples were
taken, following which volunteers were asked to consume the
test meal within 15min. Volunteers were blinded to the meal
type. Fasting and postprandial blood samples were collected at
regular time points over 3 h. Subjective hunger, nausea, desire
to eat, prospective food intake and fullness were assessed at
the same time points using visual analogue scales (VAS).
Palatability of the test meal was assessed at 15min following
consumption. VAS were analysed by measuring the distance in
millimetres from the null extremity to the mark.
Plasma samples for GLP-1 and PYY analysis were collected
into lithium heparin tubes containing aprotinin (Trasylol, 20 μl/
ml of whole blood; Nordic Pharma) on ice and immediately
centrifuged and separated. Serum samples for glucose and
insulin analysis were left to coagulate at room temperature for
15min before being centrifuged and separated. All samples
were stored at −20°C until analysis at the end of the study.
Part A: appetite, energy intake, gastrointestinal hormones
and glucose homeostasis study
Test meal. A 350 g risotto containing low (44g), medium (88g) or
high (132g) contents of mycoprotein or equivalent amounts of
protein from chicken was served in a randomised order on six
separate occasions (Table 2). All meals were designed to closely
match for energy content. Mycoprotein and chicken meals at each
protein content were designed to closely match for energy and
macronutrient content. Table 2 presents the mean energy and
macronutrient content of the meals obtained by two nutritional
analyses carried out by independent nutritional companies.
Vegetables, rice, water, cheese, oil and pesto were used to achieve
weight and macronutrient matching. The main difference in
nutritional composition resulted from the ﬁbre content, which was
not matched between meals.
Assessment of energy intake. At the end of the 3-h period,
participants were served the meal that they had chosen during
the screening visit. This ad libitum meal was served in excess,
and participants were asked to eat until they were comfortably
full. Participants were isolated during this feeding part of the
study. The ad libitum meal was weighed before and after, and
energy intake was calculated from the manufacturer’s nutri-
tional information. Participants were then free to leave the unit
but were asked to keep a detailed record of their food intake
over the following 24 h. Volunteers were asked to provide
details regarding the method of cooking, the quantities using
measurements such as cups or tablespoons, the detail of the
brands and speciﬁc details about the food (packaging for
commercial meals). Instructions and examples were provided
to the participants. Any unclear recording was further clariﬁed
with the participant. The food questionnaires were analysed by
an independent researcher trained in nutritional analysis. Food
portion sizes were estimated using Food Standards Agency
portion size references, and energy and macronutrient intake
were calculated using DietPlan 6.50 (Forestﬁeld Software Ltd).
Blood samples. Serum concentrations of glucose were measured
by enzymatic method at the end of the study using an Abbott
Architect ci8200 analyzer in the Department of Biochemistry
at Hammersmith hospital. Insulin-like immunoreactivity was
measured by RIA using a Millipore Human Insulin Speciﬁc RIA
Kit (Millipore Corporation) according to the manufacturer’s
speciﬁed protocol. PYY-like and GLP-1 immunoreactivity was
measured with an established in-house RIA(24,25). Samples for
insulin, PYY and GLP-1 analyses were assayed in duplicate.
For the PYY RIA, the antibody cross-reacted fully with the
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Fig. 1. Protocol of the study visits. Participants arrived at 08.30 hours in a fasted state. The test meal consisted of a standardised mycoprotein or chicken risotto. The
ad libitum meal was consumed 180 min after the test meal until the participant was fully satisfied. Paracetamol was given in part B as a surrogate measurement of
gastric emptying. VAS, visual analogue scale.
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biologically active circulating forms of PYY (PYY3–36 and PYY1–36)
but not with pancreatic polypeptide or other known GI
hormones. The detection limit of the PYY assay is 2·5pmol/l, and
the reported in-house intra- and inter-assay variations are 5·8 and
9·8%, respectively. For the GLP-1 RIA assay, the antibody
cross-reacted 100% with all amidated forms of GLP-1, but did not
cross-react with glycine-extended forms (GLP1–37 and GLP7–37) or
any other known pancreatic or GI peptide. The limit of detection
is 7·5pmol/l, and the reported in-house intra-assay and inter-
assay variations are 5·4 and 11·5%, respectively.
Fasting baseline measurements were averaged to obtain a
unique baseline value before statistical analysis.
Insulin sensitivity. Postprandial insulin sensitivity was esti-
mated using the Matsuda Index(26), β-cell output was estimated
using the insulinogenic index(27) and β-cell function in the
context of insulin resistance was estimated using the disposition
index(28).
Part B: gastric emptying, energy expenditure and substrate
oxidation study
Test meal. The same high-mycoprotein meal (132 g) risotto or
matched chicken meal from part A was served in a randomised
order on two separate occasions. The test meal was served with
2 g of paracetamol dissolved in 250ml of water to assess gastric
emptying. Participants were asked to consume the food and
drink within 15min and at the same rate on both occasions.
Indirect calorimetry. Upon arrival in the morning, fasted
participants were asked to void. Throughout their visit, they
were asked to collect all urine into a container and to void again
into the container at the end of the visit for the measurement of
urinary N excretion from urea. The total time of urine collection
was recorded. Resting energy expenditure (REE) was measured
at baseline and every hour for 3 h by open-circuit indirect
calorimetry (Gas Exchange Monitor; GEM Nutrition). Before
each measurement, the calorimeter was calibrated with ‘zero’
(0·00% O2, 0·00% CO2) and ‘span’ (20·00% O2, 1·00% CO2)
gases (BOC Gases). The volunteers were asked to lie in a semi-
recumbent position under the canopy and were allowed to
watch television, read or listen to music. The measurements
were ﬁrst allowed to stabilise for 10–15min, following which
the VO2 and VCO2 were recorded every minute for 15min.
The mean of the last 10 VO2 and VCO2 measurements was
calculated; any value exceeding mean (SD 2) was excluded. No
buffet meal was served at the end of the study.
Resting energy expenditure and substrate oxidation. REE
was estimated from VO2 and CO2 production in a given time
using the following equation by Weir(30). Measurements of VO2
and CO2 production were used to quantify substrate oxidation
in the body(31).
Blood samples. Serum concentrations of glucose and
paracetamol were measured by enzymatic method at the end of
the study using an Abbott Architect ci8200 analyzer (Abbott
Diagnostics) in the Department of Biochemistry at Hammersmith
hospital. Cumulative paracetamol concentrations were used to
calculate percentage paracetamol absorption from 0% (at t= 0)
to 100% (at 180min) and percentage gastric emptying (from 100
to 0%). Each individual gastric emptying curve was adapted to
a third-degree polynomial. The T50 (time to reach 50%
of gastric emptying) was interpolated from the non-linear ﬁt, as
described in a previous study by Näslund et al.(29). Insulin-like
immunoreactivity was measured by RIA using a Millipore Human
Insulin Speciﬁc RIA Kit according to the manufacturer’s speciﬁed
protocol. Fasting baseline measurements were, similarly to
part A, averaged to obtain a unique baseline value before
statistical analysis.
Statistical analysis
Results are presented as mean values and standard deviations
or as geometric mean with 95% CI of the mean. All results were
initially analysed by repeated-measures linear mixed model.
The main effects included protein type (chicken v.mycoprotein),
protein content (low, medium, high), as well as time for plasma
and serum samples and appetite ratings. Interactions between
protein type and content and protein type and time were
included in the ﬁnal model when signiﬁcant. Signiﬁcant inter-
actions are mentioned in the results section when signiﬁcant
only. Relevant covariates, such as sex, age and BMI, were
included in the initial model and removed if their effect was not
signiﬁcant. For time-proﬁle variables, the baseline value was
included as a covariate in order to correct for baseline differ-
ences, and correlation matrices of residuals were chosen by
assessing the model by −2 log likelihood. For each model, the
Table 2. Quantities of mycoprotein and chicken and nutritional composition of the test meals
Quantities Nutritional composition per serving
MP C Energy (kJ) Energy (kcal) CHO (g) Fat (g) Protein (g) Fibre (g)
High MP 132 − 1862 445 26 8 37 10
High C − 66 1774 424 25 9 40 3
Medium MP 88 − 1820 435 26 9 31 8
Medium C − 44 1749 418 29 8 30 3
Low MP 44 − 1749 418 28 9 24 6
Low C − 22 1703 407 30 9 23 4
MP, mycoprotein; C, chicken; CHO, carbohydrates.
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distribution of the residuals was checked for normality. The
homoscedasticity of the residuals was checked by plotting the
observed values against the predicted values. When the mixed
model was not validated, data were log-transformed and ana-
lysed by mixed model or analysed directly by non-parametric
tests, as described. All post hoc tests were carried out using
Bonferroni’s corrections. Statistical analysis was performed on
SPSS version 21 (IBM Corporation).
1H NMR spectroscopy-based metabonomic analysis
1H NMR spectroscopic proﬁles were obtained from plasma and
urine samples collected from volunteers involved in parts A and B,
respectively. Samples were prepared using the protocols out-
lined by Beckonert et al.(32). All spectroscopic analyses were
performed on a 700MHz Bruker NMR spectrometer, operating
at 300K and equipped with a 5mm 1H(13C/15N) inverse
cryoprobe. For each urine sample, a standard one-dimensional
NMR spectrum was acquired with water peak suppression using
a standard pulse sequence. For each spectrum, eight dummy
transients and 128 transients were collected into 64K data
points with a spectral width of 12·001 parts per million. For the
plasma samples, water-suppressed Carr–Purcell–Meiboom–Gill
spin-echo spectra were recorded. In this experiment, eight
dummy transients were followed by 128 transients and
collected in 64K data points. 1H NMR spectra were manually
corrected for phase and baseline distortions. Urine samples
were referenced to the trimethylsilylpropionic acid (TSP) singlet
at δ 0·0, and plasma samples were referenced to the anomeric
proton of β-glucose at δ 5·223. Spectra were digitised using an
in-house MATLAB (version R2009b; The Mathworks, Inc.)
script. To minimise baseline distortions arising from imperfect
water saturation, the region containing the water resonance was
excised from the spectra. Orthogonal projection to latent
structures-discriminant analysis (OPLS-DA) was performed in
MATLAB using scripts provided by Korrigan Sciences Ltd. Here,
the spectroscopic proﬁles served as the descriptor matrix, and
class membership (chicken and mycoprotein diet) was used as
the response variable. Further OPLS models were constructed
using volunteer metrics (fat-free mass) and outcome measures
(fullness and hunger) as continuous response variables to illu-
minate associated metabolic variation. Correlation coefﬁcients
plots were constructed from the model outputs by back-scaling
transformation to display the contributions of each metabolite to
sample classiﬁcation. Colour represents the signiﬁcance of
correlation for each metabolite to class membership. The pre-
dictive ability (Q2Y) of each model was calculated using a 7-fold
cross-validation approach, and model validity was established
by permutation testing (1000 permutations).
Results
Volunteers
Part A of the study was completed between August 2010 and
September 2011. Part B of the study was completed between
April 2012 and September 2012. A total of 293 volunteers
contacted the research team, ninety-two were screened and
sixty-six were randomised into the study. A total of sixteen
participants withdrew from the study for various reasons (dislike
of the meals, dislike of the protocol, repeated difﬁculties with
catheter insertion or blood sampling, unplanned pregnancy).
Part A: appetite, energy intake, gastrointestinal hormones
and glucose homoeostasis study
Volunteers. A total of thirty-six volunteers (age 33 (SD 14) years,
BMI 28·1 (SD 2·3) kg/m2) completed the study. Baseline
characteristics are shown in Table 3.
Appetite ratings. As expected, there was a signiﬁcant effect of
time on all appetite ratings. Hunger, desire to eat and pro-
spective food intake mean ratings signiﬁcantly decreased fol-
lowing the consumption of the test meal between 0 and 15min
and thereafter increased slowly. Conversely, fullness sig-
niﬁcantly increased following the consumption of the test meal
and slowly decreased throughout the following 3 h (Fig. 2).
There were no differences in sickness ratings following the
consumption of mycoprotein compared with chicken.
Table 3. Baseline characteristics of volunteers
(Mean values and standard deviations)
Part A Part B
Mean SD Mean SD
Age (years) 33 14 37 18
Sex 19 males/17 females 5 males/9 females
Height 168·5 9·5 170·0 8·5
Weight (kg) 80·2 12·0 82·7 12·5
BMI (kg/m2) 28·1 2·3 28·4 2·5
Ethnic origin
White 20 5
Asian 6 2
African 3 5
Other 7 2
Fat mass (kg) 26·9 9·0
Fat-free mass (kg) 54·9 11·3
Body fat (%) 32·7 8·6
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There were no signiﬁcant differences in hunger, desire to eat
and prospective food intake ratings at any time points between
mycoprotein and chicken. There was a trend towards increased
fullness following the consumption of mycoprotein compared
with chicken (P= 0·066). Post-test showed a signiﬁcant effect
of the treatment at the high-protein content at 150min (chicken
46 (SD 4), mycoprotein 55 (SD 4), P= 0·03) and 180min (chicken
39 (SD 4), mycoprotein 47 (SD 4), P= 0·04) (Fig. 2(c)).
Consistent with our results on energy intake from part A,
there was no effect of the protein content per se on any of
the appetite ratings overall or in mycoprotein and chicken
separately.
Energy intake at ad libitum meal. The energy intake at the
ad libitum lunch following the different test meals is shown in
Fig. 3(a). There was a signiﬁcant effect of the type of protein
(mycoprotein v. chicken) on energy intake (P= 0·008): overall,
mycoprotein signiﬁcantly decreased energy intake at the ad
libitum meal further than the chicken test meal (chicken 2657
(SD 155) kJ (635 (SD 37) kcal), mycoprotein 2494 (SD 155) kJ (596
(SD 37) kcal)). Post-tests showed that energy intake following
the high-mycoprotein meal was 10% (280 kJ (67 kcal)) lower
than following the chicken test meal (mean energy intake (EI)
high chicken: 2711 (SD 234) kJ (648 (SD 56) kcal), mean EI high
mycoprotein: 2431 (SD 209) kJ (581 (SD 50 kcal)), P= 0·009).
Differences in energy intake between chicken and mycoprotein
at the low and medium levels were not signiﬁcant.
The content of protein did not have any signiﬁcant effect on
energy intake: a higher content of protein did not induce a greater
reduction in energy intake compared with the low and medium
contents of protein overall, or for chicken and mycoprotein
separately.
As expected, there was a signiﬁcant effect of sex on energy
intake (P<0·001), with males eating signiﬁcantly more than
females.
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Fig. 2. Fullness ratings over time at low (a), medium (b) and high (c) protein contents following the consumption of mycoprotein and chicken. Values are means, with
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Fig. 3. Energy intake at ad libitum meal (a) and during the following 24 h (b). Values are means, with standard errors represented by bar charts. * P≤ 0·05, ** P≤ 0·01
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Participants found the mycoprotein signiﬁcantly less pleasant
than the chicken meal. However, mean palatability ratings
remained above 60 out of 100 for both meals (mean palatability
score chicken: 71 (95% CI 64, 77), mycoprotein: 65 (95% CI
59, 72), P=0·023).
24-h energy intake. There was a signiﬁcant effect of the type
of protein on energy intake at 24 h (P= 0·027): mean energy
intake over 24 h was reduced by 787 kJ (188 kcal) (9%)
following the consumption of mycoprotein compared with
chicken (chicken: 9209 (95% CI 8351, 10071) kJ (2201 (95% CI
1996, 2407) kcal), mycoprotein: 8422 (95% CI 7552, 9288) kJ
(2013 (95% CI 1805, 2220) kcal)) (Fig. 3(b)). Post-tests showed
a signiﬁcant difference at the low content (P= 0·047) and
approaching signiﬁcance at the high content (P= 0·083).
Similarly to the acute energy intake results, there was no
signiﬁcant effect of the protein content per se on energy intake
over 24 h overall, or in mycoprotein and chicken separately.
Peptide tyrosine-tyrosine and glucagon-like peptide-1
concentrations. Plasma GLP-1 and PYY concentrations fol-
lowing the consumption of the high-protein chicken and
mycoprotein test meals are shown in Fig. 4.
There was a signiﬁcant effect of time on GLP-1 concentra-
tions (P< 0·001). Following the consumption of the test meal,
GLP-1 concentrations increased then decreased. PYY did not
show such a pronounced postprandial excursion.
No signiﬁcant effect of the protein type was observed on
GLP-1 and PYY concentrations.
Glucose and insulin concentrations. Fig. 5(a–c) shows baseline
and postprandial serum concentrations of glucose at low, medium
and high protein contents over 180min. As expected, there was a
signiﬁcant effect of time on glucose concentrations (P<0·001).
Following the consumption of all test meals, glucose concentra-
tions increased to reach a maximum at 30min and thereafter
returned to baseline concentrations. There was no signiﬁcant
effect of the type and level of protein on glucose concentrations
at any time point. Fig. 5(d–f) shows baseline and postprandial
serum concentration of insulin at low, medium and high protein
content over 180min. There was a signiﬁcant effect of time on
insulin concentrations (P< 0·001). Insulin concentrations
increased following the consumption of the test meal to reach a
maximum at 30–45min and returned to baseline within 2 h.
There was a signiﬁcant effect of the time× type of
protein interaction (P= 0·002) on insulin serum concentrations:
mycoprotein signiﬁcantly reduced insulin concentration com-
pared with chicken.
At the high-protein content, mycoprotein signiﬁcantly
reduced insulin concentrations compared with chicken by 41%
at 15min, 27% at 30min, 20% at 45min, 21% at 60min and
26% at 90min. At the medium level of protein, mycoprotein
reduced insulin concentrations compared with chicken by 22%
at 15min, 12% at 30min, 12% at 45min, 13% at 60min and
24% at 90min. There was no signiﬁcant effect of the protein
content on insulin concentrations at other time points.
Analysis of the incremental AUC (IAUC) showed a signiﬁcant
effect of the type of protein overall (P= 0·004) (Table 4). Post-
tests showed a signiﬁcant reduction in insulin IAUC of 8% at
low (P= 0·024), 12% at medium (P= 0·001) and 21% at high
content of protein (P< 0·001).
There was a signiﬁcant effect of the protein content on insulin
IAUC (P= 0·005). Post-tests showed that the effect of the
protein content was signiﬁcant for chicken (P= 0·016) but not
for mycoprotein (Table 4). The high level of chicken induced
signiﬁcantly higher insulin concentrations compared with the
medium level, with no signiﬁcant difference between low and
medium and low and high levels.
Insulin sensitivity. Matsuda, Insulinogenic and Disposition
Indices, shown in Fig. 5(g–i), were log-transformed before
analysis. Overall, there was a signiﬁcant effect of the type of
protein on Matsuda Index (P= 0·026), Insulinogenic Index
(P= 0·001) and Disposition Index (P= 0·007). Mycoprotein
improved insulin sensitivity compared with chicken, as shown
by a signiﬁcantly higher Matsuda Index (chicken: 78 (95% CI
70, 86), mycoprotein: 84 (95% CI 76, 92), P= 0·026 for log-
transformed data). Post-tests at each level showed a signiﬁcant
difference between mycoprotein and chicken at the high-
protein content (high chicken: 64·0 (95% CI 54·7, 74·8), high
mycoprotein: 70·9 (95% CI 62·0, 81·0), P= 0·041 for log-
transformed data) but not at the medium and low levels.
Mycoprotein signiﬁcantly reduced the Insulinogenic Index by
21% compared with chicken (Insulinogenic Index chicken: 43
(95% CI 37–48), Insulinogenic Index mycoprotein: 34 (95% CI
29–39), P= 0·001 for log-transformed data). Post-tests showed
that mycoprotein reduced the Insulinogenic Index compared
with chicken by 18% at the low-protein content (low chicken:
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38 (95% CI 31, 47), low mycoprotein: 31 (95% CI 25, 39),
P= 0·011), 15% at the medium-protein content (medium
chicken: 33 (95% CI 25, 43), medium mycoprotein: 28 (95% CI
22, 37), P= 0·09) and 30% at the high-protein content (high
chicken: 43 (95% CI 36, 53), high mycoprotein: 30 (95% CI 23,
39), P= 0·006). Mycoprotein signiﬁcantly reduced the
Disposition Index by 16% compared with chicken (Disposition
Index chicken: 3355 (95% CI 2944, 3766); Disposition
Index mycoprotein 2832 (95% CI 2421, 3244), P= 0·007
for log-transformed data). Post-tests showed signiﬁcant
differences between mycoprotein and chicken at the high-
protein content (high chicken: 3392 (95% CI 2398, 4384), high
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Fig. 5. Plasma glucose and serum insulin concentrations at low, medium and high-protein contents and insulin sensitivity following the consumption of mycoprotein
and chicken. (a–c) Plasma glucose concentrations at low (a), medium (b) and high (c) protein contents. (d–f) Serum insulin concentrations at low (d), medium (e) and
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mycoprotein: 2461 (95% CI 1903, 3020), P= 0·028) but not at
medium and low protein contents.
There was a signiﬁcant effect of the content of protein on the
Matsuda Index (P< 0·001). Post-test within protein types
showed a signiﬁcant effect of the protein content in both
mycoprotein (P= 0·017) and chicken (P= 0·002). The Matsuda
Index following the high-protein content was signiﬁcantly
lower compared with that from the low-protein content for
chicken (high chicken: 64 (95% CI 55, 65), low chicken: 78
(95% CI 68, 90), P= 0·012) and almost signiﬁcantly lower for
mycoprotein (high mycoprotein: 71 (95% CI 62, 81), low
mycoprotein 83 (95% CI 72, 95), P= 0·059).
Part B: gastric emptying, energy expenditure and substrate
oxidation study
A total of fourteen volunteers (nine females and ﬁve males,
mean age: 37·2 (SD 4·5) years, mean BMI: 28·4 (SD 0·6) kg/m2)
completed the study. Baseline characteristics are shown in
Table 3.
Appetite ratings. Similarly to results from part A, there was a
signiﬁcant effect of time (P< 0·001) on all appetite ratings apart
from sickness (Fig. 6).
There was no signiﬁcant effect of mycoprotein on hunger,
sickness, desire to eat, prospective food intake and fullness at
any time point compared with chicken. This was conﬁrmed by
the overall analysis of the IAUCAUC showing no signiﬁcant
effect of the protein type (Fig. 6).
Glucose and insulin concentrations. In line with previous
ﬁndings from part A, there was no signiﬁcant difference in
plasma glucose concentrations following the consumption of
mycoprotein and chicken (IAUC glucose chicken: 1006 (SD 95),
IAUC glucose mycoprotein: 1004 (SD 92), NS).
Analysis of the insulin IAUC showed that insulin concentra-
tions were signiﬁcantly lower following the consumption of
Table 4. Incremental AUC for glucose and insulin
(Mean values with standard errors; geometric means with 95% confidence interval adjusted for age)
Low Medium High
C MP C MP C MP
Mean SEM Mean SEM P Mean SEM Mean SEM P Mean SEM Mean SEM P
Glucose IAUC (mmol/min per litre)
Insulin IAUC (μU/min per litre)
1019 13 1006 14 NS 983 13 992 9 NS 1013 17 976 14 NS
Mean 10364a,b 9481 0·024 9650a 8510 0·001 11178b* 8884 <0·001
95% CI 8837, 11 891 7954, 11 008 8571, 10 728 7431, 9588 9604, 12 752 7311, 10 458
C, chicken; MP, mycoprotein; IAUC, incremental AUC.
a,b Mean values with unlike superscript letters were significantly different.
* P values and letters correspond to mixed model post-test comparisons between low, medium and high protein content for each treatment and are given with Bonferroni’s correction
(P= 0·029).
80
60
40
20
0
80
60
40
20
0
80
60
40
20
0
80
60
40
20
0
0 30 60 90 120 150 180 0 30 60 90 120 150 180
0 30 60 90 120 150 180 0 30 60 90 120 150 180 0 30 60 90 120 150 180
100
H
un
ge
r s
co
re
 (m
m)
N
au
se
a 
sc
or
e 
(m
m)
D
es
ire
 to
 e
at
 s
co
re
 (m
m)
Time (min)
Time (min) Time (min)
Time (min) Time (min)
Pr
os
pe
ct
ive
 fo
o
d 
in
ta
ke
sc
o
re
 (m
m)
Fu
lln
es
s 
sc
or
e 
(m
m)
100
80
60
40
20
0
IA
UC
 (m
m2
)
15 000
10 000
5000
0
Hunger Nausea Desire
to eat
Prospect
FI
Fullness
(a) (b) (c)
(d) (e) (f)
Fig. 6. Appetite ratings following the consumption of mycoprotein and chicken: hunger (a), nausea (b), desire to eat (c), prospective food intake (d), fullness (e) and
IAUC for all appetite ratings (f). Values are means, with standard errors. IAUC, incremental AUC. , Chicken; , mycoprotein.
368 J. H. Bottin et al.
mycoprotein than following the consumption of chicken (IAUC
insulin chicken 10693 (SD 4117), IAUC insulin mycoprotein:
9288 (SD 3076), P= 0·015).
Gastric emptying. There was no difference in paracetamol
concentrations (Fig. 7(a)) or percentage gastric emptying
(Fig. 7(b)) over time between mycoprotein and chicken. The
T50 was 65min for mycoprotein and 66min for chicken (NS).
As expected, there was a signiﬁcant effect of time (P< 0·001)
on paracetamol concentrations, with paracetamol concentra-
tions increasing rapidly following the consumption of the test
meal to reach a maximum and slowly decreasing over the fol-
lowing 3 h (Fig. 7(a)).
There was no difference in paracetamol concentrations at any
time point following the consumption of mycoprotein or
chicken (Fig. 7(a)). Analysis of the AUC showed no signiﬁcant
differences in paracetamol concentrations between myco-
protein and chicken overall. No signiﬁcant differences in time-
to-peak were observed.
Resting energy expenditure and substrate oxidation. There
was a signiﬁcant effect of time on REE (P< 0·001). REE
increased following the consumption of the test meal. No sig-
niﬁcant difference in REE was observed following the con-
sumption of mycoprotein compared with chicken (Fig. 8(a)).
RER, carbohydrate oxidation (OXCHO) and fat oxidation
(OXFAT) are shown in Fig. 8(b–d). There was no signiﬁcant
effect of time on the RER (Fig. 8(b)) and the OXFAT (Fig. 8(d)).
Analysis of the OXCHO showed a signiﬁcant effect of time
(P< 0·001), with OXCHO increasing following consumption of
the test meal (Fig. 8(c)).
The analysis showed no signiﬁcant effect of the protein type
on RER, OXCHO and OXFAT at any time points (Fig. 8).
Metabonomics analysis
An OPLS-DA model with good predictive ability (Q2Y=0·60)
was obtained comparing the urinary metabolic proﬁles of
volunteers following chicken and mycoprotein intake (Fig. 9(a)).
Mycoprotein consumption resulted in the greater excretion
of guanidinoacetic acid (GAA), whereas excretion of 1-
methylhistidine was observed with chicken intake. An unknown
metabolite (δ 2·48 (singlet)) was also excreted in greater amounts
following mycoprotein ingestion compared with the chicken diet.
An OPLS-DA model was constructed to compare the plasma
metabolic proﬁles 30 v. 180min after mycoprotein consumption
(Fig. 9(b); Q2Y= 0·6). This model was consistent with the plasma
glucose measures showing blood glucose to be higher at 30min
than at 180min. At the later time point, the branched-chain amino
acids, leucine, isoleucine and valine, were found to be higher in
the blood. N-acetylglycoproteins, markers of inﬂammation, were
also present at higher amounts 180min post mycoprotein con-
sumption compared with the earlier sampling point.
Separate OPLS models were constructed to identify metabolic
variation associated with fullness following mycoprotein
(Fig. 10(a)) and chicken (Fig. 10(b)) intake. Signiﬁcant models
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were returned for both diets (chicken Q2Y= 0·475; mycoprotein
Q2Y = 0·429), but variation was observed in the metabolites
associated with fullness. Following chicken intake, paracetamol-
glucuronide was positively associated with fullness, whereas
creatinine was negatively associated. After mycoprotein
consumption, creatinine and the deamination product of
isoleucine, α-keto-β-methyl-N-valerate, were inversely related to
fullness, whereas the ketone body, β-hydroxybutyrate, was
positively associated.
Discussion
We hypothesised that mycoprotein would reduce the energy
intake in overweight and obese individuals in a dose-
dependent manner, and this would be mediated by changes
in appetite regulating GI hormone concentrations. Conﬁrming
previous ﬁndings in lean individuals(21,22), this is the ﬁrst study
showing that the consumption of 132 g of mycoprotein by
healthy overweight and obese adults reduces energy intake by
10% at an ad libitum meal compared with a macronutrient-
matched meal containing chicken. Low and medium quantities
of mycoprotein did not reduce energy intake, suggesting that a
minimum amount of mycoprotein is needed to affect appetite. If
mycoprotein was consumed regularly and its effect maintained
over the long term, this 10% reduction in energy intake may
represent a signiﬁcant weight loss. The present study also
showed that mycoprotein reduced energy intake by a further
9% over 24 h compared with chicken; however, a signiﬁcant
effect was only observed at the lower content of protein.
Although we do not have a clear explanation for this observa-
tion, it is possible that the study was underpowered to look at
differences in 24-h energy intake or that underestimation or
poor completion of the food diaries, which are both common in
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overweight human volunteers, increased the error in measure-
ment of energy intake. In line with previous ﬁndings by Burley
et al.(21), no signiﬁcant effects of mycoprotein consumption on
appetite ratings were noted. Although the use of VAS is common
in appetite studies, the sample size needed to detect signiﬁcant
small differences in appetite ratings after statistical correction for
multiple comparisons was possibly not reached in this study.
We found that the protein content of the meal (low, medium,
or high) did not have any signiﬁcant effect per se on energy
intake at the ad libitum meal. Although previous studies have
suggested a negative dose–response in appetite to increasing
contents of protein, differences in protein content in those
studies (13–26 g in the study by Astbury et al.(34)) were greater
than in our study (6–10 g)(33–35). Consequently, the differences
in protein content in our study may not have been sufﬁcient to
induce signiﬁcant reductions in energy intake. Previous studies
using greater differences in protein intake also showed no effect
on appetite ratings(34).
The investigations of the mechanisms underlying the mode of
action of mycoprotein were inconclusive. Part A of our study
showed that mycoprotein did not induce a signiﬁcant increase
in GLP-1 and PYY plasma concentrations compared with the
chicken meal, suggesting that the reduction in energy intake is
not mediated by changes in the release of these hormones.
Furthermore, although there was an increase in GLP-1
concentrations following the consumption of the test meal in
our study, no postprandial increase in PYY concentrations
could be detected, suggesting that the energy load of the meal
was not sufﬁcient to induce a detectable increase in PYY. Other
GI hormones may have played a role in the energy intake
reduction following mycoprotein intake. Further studies should,
for example, investigate the role of cholecystokinin, which has
been shown to be associated with gastric distension and to play
a role in appetite regulation.
Using the paracetamol method, no signiﬁcant differences in
gastric emptying following the consumption of the mycoprotein
and chicken test meals were found. The paracetamol method
can be used as a proxy to estimate gastric emptying rate in solid
meals, as it is a relatively inexpensive replacement to the
scintigraphic, polyethylene glycol dilution and 13C acetate
breath test methods(36,37). Consistent with previous studies,
paracetamol was supplied to the participants in a liquid form.
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However, participants consumed the paracetamol drink along
with their meal in our study, whereas paracetamol was given
at the end of a solid meal in previous studies. Although
participants were asked to keep a similar constant drinking
pace during both visits, it is possible that because mycoprotein
is bulkier the rate of drinking was faster than during the chicken
test meal. This may be clariﬁed by mixing paracetamol directly
within the test meal in future studies. Alternatively, mycoprotein
may modulate gastric distension or intestinal transit time
without affecting gastric emptying, as its energy density is lower
than that of chicken.
In the second part of our study, mycoprotein did not induce
signiﬁcant changes in energy expenditure. Matching of the test
meals for protein content may explain this observation,
as protein has been shown to increase energy expenditure
independently of the energy content in previous studies(38).
Changes in RER and substrate oxidation were not signiﬁcant. As
this area of research is relatively new, there are no studies
directly investigating the effect of ﬁbre supplementation on
substrate oxidation. The amount of ﬁbre contained in myco-
protein may not be sufﬁcient to induce acute changes in sub-
strate oxidation. Whether prolonged supplementation of
mycoprotein could induce signiﬁcant alterations in substrate
oxidation over the long term is unknown, but it is unlikely that
this would be the main mechanism of action of mycoprotein.
The main difference between the test meals resulted from the
ﬁbre content. The ﬁbre contained in mycoprotein, composed of
chitin and β-glucan linked in a strong matrix, is 88% insoluble.
This suggests that the insoluble ﬁbre may be the main active
compound in mycoprotein. Chitin is generally absent from the
diet of humans, and its impact in the GI tract is poorly under-
stood. It may be resistant to digestion, as its structure is similar
to that of cellulose and xylose. The largely insoluble β-glucan in
mycoprotein is different from soluble plant-derived β-glucan
originating from barley and oats, which have been shown to
reduce energy intake, act on intestinal transit and glucose
homoeostasis and modulate GI hormone release in several
animal and human studies(12–14,39). It is possible that, although
of different structure and properties, mycoprotein β-glucan
presents common characteristics and acts in a similar way.
Although there have been few studies that have investigated the
digestion of mycoprotein in the GI tract(40,41), its effects on
appetite regulation remain to be explored. It would be inter-
esting to extract digested mycoprotein from the GI tract of
animals and analyse its composition at regular time intervals
following oral ingestion.
Our study found that mycoprotein did not induce any sig-
niﬁcant changes in glycaemic response compared with chicken,
which is consistent with ﬁndings by Marks et al.(42,43). Although
Turnbull et al. found a signiﬁcant reduction in glucose con-
centration at 60min following the consumption of mycoprotein
compared with a soya meal, the design of their study differed
considerably, because they used a liquid oral glucose tolerance
test-like meal containing soya, milk and mycoprotein powder.
Consistent with previous ﬁndings, our study showed that
mycoprotein reduced postprandial serum insulin concentra-
tions by 8–21% compared with chicken in overweight and
obese individuals(20). Furthermore, analysis of the Matsuda,
Insulinogenic and Disposition Indices suggested that myco-
protein improves insulin sensitivity and reduces β-cell output
without altering glucose concentrations. More robust measure-
ments of insulin sensitivity assessment, such as the hyper-
insulinaemic euglycaemic clamp, should be used to conﬁrm
whether mycoprotein results in the sparing of the β-cells
following a long-term intervention. Our hypothesis is that the
structure of mycoprotein itself plays a role in the regulation of
glucose metabolism following oral ingestion by limiting carbo-
hydrate absorption in the intestine. Native mycoprotein paste is
composed of β-glucan-chitin ﬁlaments of various lengths ran-
domly oriented in all directions and bound by a gel matrix(44).
In a previous study investigating the impact of the length of
mycoprotein ﬁlaments, Marks found that 90 g of mycoprotein
containing long ﬁlaments delayed gastric emptying compared
with the same quantity of mycoprotein containing short
ﬁlaments(43). Although no difference in gastric emptying was
found in our study, it does imply that the structure and length of
the ﬁlaments play a role in the digestion of mycoprotein.
To further understand the mechanism through which myco-
protein modulates appetite regulation, the urinary and plasma
metabolic proﬁles were studied across the participants. Multi-
variate statistical analysis of the urinary proﬁles identiﬁed that
1-methylhistidine was excreted in greater amounts following
consumption of chicken. This metabolite derives from the
breakdown of anserine and has been previously reported as a
biomarker of meat consumption. Indeed, Sjolin et al.(45) have
shown urinary 1-methylhistidine to be associated with chicken
ingestion.
Following mycoprotein consumption, a greater excretion of
GAA was observed compared with chicken intake. GAA is a
methyl-group acceptor and the precursor for creatine; as such, it
is an essential substrate for muscle energy metabolism. It can be
synthesised endogenously from arginine and glycine in the liver
and kidneys. Although there is lack of data on the role of GAA
in humans, dietary GAA has the potential to spare dietary
arginine. Recently, there is preliminary evidence that arginine
may play a role in appetite regulation(46,47). Another metabolite
was excreted in greater amount following mycoprotein inges-
tion, although we were unable to identify it in the context of this
study. In response to the mycoprotein diet, it is a possible to
speculate that the ketone body β-hydroxybutyrate was found to
be positively associated with fullness. This was not observed in
response to the chicken diet. β-Hydroxybutyrate has been
previously linked to appetite suppression through central
effects at the hypothalamus. β-Hydroxybutyrate is normally
associated with long-term fasting; in the case of this study, the
volunteers were in a fed state. At present, the unique associa-
tion between β-hydroxybutyrate and fullness with the myco-
protein diet remains unclear. It does raise an interesting
possible explanation for the appetite suppression, which would
be worthy of further study.
Conclusion
Our results demonstrate for the ﬁrst time in overweight and
obese volunteers that mycoprotein acutely reduces energy
intake and improves glycaemic proﬁle. Our study was not able
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to provide a clear mechanistic explanation, although the
metabonomics analysis did identify candidate biomolecules that
warrant further investigation. There is need of longer-term
studies to investigate the potential of mycoprotein in the
prevention of obesity and T2DM.
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